-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the data released by miR Scientific at the annual meeting of the American Urological Association (AUA) showed that its technology of using urine to detect prostate cancer can accurately detect prostate cancer at the molecular level and classify its risk
.
The detection technology only requires a urine sample, and the prediction accuracy rate exceeds 90%
This prostate cancer detection technology, called miR Sentinel, has been certified by the FDA as a breakthrough medical device.
It is a non-invasive molecular test based on the analysis of small non-coding RNA (sncRNA) in exosomes in urine
.
It provides an innovative method to analyze sncRNAs in urine samples.
Image source: miR Scientific's official website
When comparing the results of miR Sentinel detection technology with systematic needle biopsy among men who were initially suspected of prostate cancer, the study showed that the consistency of the two screening and detection methods in the classification of clinically significant cancer was 93%
.
The data further proved that the miR Sentinel test correctly identified 96% (371/387) of men with non-clinically significant cancer
(The original text has been deleted)
Reference materials:
[1] miR Scientific Presents Groundbreaking Data on the Exceptional Accuracy of its Prostate Cancer Liquid-Biopsy Test.
